Bioengineered Dendritic Cells for Lymph Node Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering dendritic cells (DC) in cancer treatment face limitations, including limited movement to lymph nodes and ineffective intravenous delivery, which restricts immune responses and makes it impractical to target multiple lymph nodes, especially in chemotherapy-induced shrinkage scenarios.
Innovation Solution
Bioengineered dendritic cells expressing chemokines are used to attract and activate immune cells, creating a functioning lymph node-like structure at the injection site, thereby enhancing immune responses and antigen presentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendritic cells are delivered via subcutaneous or intradermal injection, then they can be administered, but their movement to lymph nodes is very limited
Solution Approach 1:
Chemokines are used as intermediary signaling molecules to mediate the attraction and migration of dendritic cells to lymph nodes. The chemokines create a chemical gradient that guides cell movement, solving the problem of limited migration without requiring direct physical transport mechanisms.
Solution Approach 2:
The invention changes the chemical environment by introducing chemokines, which alters the migratory behavior of dendritic cells. By modifying the chemical parameters (chemokine concentration gradients), the cells' movement patterns are changed to enhance lymph node targeting.
2Adaptability or versatility
If dendritic cells are delivered intravenously, then multiple peripheral lymphoid organs can be targeted, but the cells are trapped in capillaries and cleared rapidly
Solution Approach 1:
Chemokines serve as intermediaries that guide dendritic cells through the bloodstream to specific lymphoid organs without causing capillary trapping. The chemokine gradient system allows cells to navigate efficiently through the circulatory system and exit at appropriate locations.
Solution Approach 2:
The chemokine gradient is established in advance within the lymphoid organs, creating a pre-positioned guidance system. When dendritic cells enter the circulation, they immediately respond to these pre-established gradients and are directed to the appropriate organs before being trapped or cleared.
3Reliability
If a large number of dendritic cells are delivered to a single lymph node, then immune response can be enhanced, but it is logistically and technically impractical
Solution Approach 1:
Instead of delivering a large number of cells to a single lymph node, the invention segments the delivery approach by using chemokine gradients to distribute cells naturally to multiple lymph nodes simultaneously. This divides the delivery task into multiple smaller, more manageable targets.
Solution Approach 2:
The dendritic cells themselves perform the localization function by responding to chemokine gradients. Rather than requiring external mechanical or surgical intervention to deliver cells to specific nodes, the cells autonomously navigate to their destinations using the chemokine guidance system.
4Reliability
If direct intranodal delivery is used, then immune response is superior, but it is impractical to target multiple lymph nodes
Solution Approach 1:
The chemokine-based delivery system provides a universal mechanism that can target multiple lymph nodes simultaneously through a single administration route. The same chemokine gradient system that guides cells to one lymph node also guides them to other nodes expressing the appropriate chemokines, providing multi-functional targeting capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively recruits immune cells to the tumor site, leading to increased activation and infiltration of T cells, resulting in enhanced antitumor immunity and tumor regression, even in the absence of peripheral lymph nodes.
Implementation Method 1
DC expressing one or more exogenous chemokines that attract and/or increase activation of lymphocytes
Implementation Method 2
The DC can be loaded with an antigen (e.g., tumor, viral, bacterial, or fungal antigens)
Data Source
AI summary
The invention provides compositions and methods of treating various conditions, including tumors, with compositions comprising dendritic cells expressing exogenous chemokines.